Delcath Systems has entered into an initial launch and training agreement with the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam. Under the terms of the agreement, Delcath will provide the NKI-AVL with logistics and clinical training support for chemosaturation therapy using the Chemosat delivery system. Training at the NKI-AVL is expected to begin in May and, upon completion, the site will become the first in the Netherlands to offer the procedure.
The hepatic Chemosat delivery system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. Delcath's initial focus is on the treatment of primary and metastatic liver cancers.